Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.
Antimicrobial susceptibility testing of 192 group B streptococcal isolates from patients with invasive disease demonstrated that 31 (16%) were resistant to erythromycin and 17 (9%) were resistant to clindamycin. One isolate demonstrated high-level resistance to streptomycin, but none was highly resistant to gentamicin. Erythromycin and clindamycin are no longer reliable empirical alternatives to penicillin for the treatment and prevention of group B streptococcal infections.
Murdoch
D R
DR
Clinical Microbiology Laboratory, Duke University Medical Center, Durham, North Carolina 27710, USA. david.murdoch@cdhb.govt.nz
Reller
L B
LB
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D011247:Pregnancy; D013290:Streptococcal Infections / Q000382:microbiology*; D013292:Streptococcus agalactiae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D018942:Macrolides